Literature DB >> 23189953

microRNAs as mediators of drug toxicity.

Tsuyoshi Yokoi1, Miki Nakajima.   

Abstract

microRNAs (miRNAs) represent the most abundant class of gene expression regulators that bind complementarily to transcripts to repress their translation or mRNA degradation. These small ( 21-23 nucleotides in length) noncoding RNAs are derived through a multistep process by miRNA genes located in genomic DNA. Because miRNAs regulate fundamental cellular functions, their dysregulation affects a large range of physiological processes, such as development, immune responses, metabolism, and diseases as well as toxicological outcomes. Cancer-related miRNAs have been extensively studied; however, the roles of miRNAs in xenobiotic metabolism and in toxicology have only recently been explored. This review focuses on the current knowledge of miRNA-dependent regulation of drug-metabolizing enzymes and nuclear receptors and the associated potential toxicological implications. The potential modulation of toxicology-related changes in miRNA expression, the role of miRNA in immune-mediated drug-induced liver injuries, the use of circulating miRNAs in body fluids as potential toxicological biomarkers, and the link between miRNA-related pharmacogenomics and adverse drug reactions are highlighted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23189953     DOI: 10.1146/annurev-pharmtox-011112-140250

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  32 in total

1.  MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.

Authors:  Xiao He; Xia Xiao; Lin Dong; Nengbin Wan; Zhengyu Zhou; Hongwu Deng; Xiefu Zhang
Journal:  Tumour Biol       Date:  2014-11-15

Review 2.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

3.  Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport.

Authors:  Magnus Ingelman-Sundberg; Xiao-Bo Zhong; Oliver Hankinson; Sudheer Beedanagari; Ai-Ming Yu; Lai Peng; Yoichi Osawa
Journal:  Drug Metab Dispos       Date:  2013-08-05       Impact factor: 3.922

Review 4.  Back to the future: transgenerational transmission of xenobiotic-induced epigenetic remodeling.

Authors:  Josep C Jiménez-Chillarón; Mark J Nijland; António A Ascensão; Vilma A Sardão; José Magalhães; Michael J Hitchler; Frederick E Domann; Paulo J Oliveira
Journal:  Epigenetics       Date:  2015-03-16       Impact factor: 4.528

5.  MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.

Authors:  Dianke Yu; Bridgett Green; William H Tolleson; Yaqiong Jin; Nan Mei; Yongli Guo; Helen Deng; Igor Pogribny; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2015-08-19       Impact factor: 5.858

6.  Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.

Authors:  Hiba Ahmad Zahreddine; Katherine L B Borden
Journal:  Clin Cancer Res       Date:  2015-03-25       Impact factor: 12.531

7.  Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells.

Authors:  Dianke Yu; William H Tolleson; Bridgett Knox; Yaqiong Jin; Lei Guo; Yongli Guo; Susan A Kadlubar; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2015-09-30       Impact factor: 5.858

Review 8.  MiRNAs-mediated cisplatin resistance in breast cancer.

Authors:  Xiu Chen; Peng Lu; Ying Wu; Dan-Dan Wang; Siying Zhou; Su-Jin Yang; Hong-Yu Shen; Xiao-Hui Zhang; Jian-Hua Zhao; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2016-07-22

9.  Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1.

Authors:  Yu-Zhuo Pan; Amy Zhou; Zihua Hu; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2013-05-16       Impact factor: 3.922

Review 10.  MicroRNAs in liver disease.

Authors:  Gyongyi Szabo; Shashi Bala
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-05-21       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.